Sanofi SA (ADR) news

   Watch this stock
Showing stories 1 - 10 of about 229   

Articles published

SNY 48.86 -0.01 (-0.02%)
price chart
Eli Lilly and Co Poses Threat To Sanofi SA (ADR) With Biosimilar Insulin
Eli Lilly & Co announced yesterday it is ready to launch Abasria, a cheaper biosimilar version of Sanofi's blockbuster diabetic drug, Lantus.
Sanofi (SNY) Stock: One Big Bet on Diabetes Drugs  Investorplace.com
Sanofi SA (ADR) (NYSE:SNY) can sell Lantus: approved by US  Investor Wired
Analyst Rating Update on Sanofi SA (ADR)
Analysts at Zacks have given a short term rating of sell on Sanofi-Aventis Sa (NYSE:SNY) with a rank of 4. The counter has received an average rating of 2.2 from 5 brokerage firms.
Price Target Update on Sanofi SA (ADR)  Markets Bureau
Sanofi SA (ADR) New CEO To Focus On US Market
Sanofi's quest to find a replacement for ousted CEO Chris Viehbacher has come to an end. It finally announced Thursday the appointment of Olivier Brandicourt, head of Bayer AG's (ADR)(OTCMKTS:BAYRY) healthcare business, as its new CEO.
Stocks Red-Hot After News: Sanofi SA (ADR) (NYSE:SNY), Vale SA (ADR ...  Investor Wired (press release)
Bayer's Brandicourt To Be Named Sanofi SA (ADR) CEO - Reports
Sanofi SA (ADR) (NYSE:SNY) has been searching for a candidate to replace its ousted Chief Executive Officer Chris Viehbacher ever since October last year; Olivier Brandicourt, head of Bayer AG (ADR)'s (OTCMKTS:BAYRY) healthcare business, might put ...
Zacks Long Term Rating Update on Sanofi SA (ADR)
As much as 5 analysts have advised buy on Sanofi SA (ADR) (NYSE:SNY) with an average broker rating of 2.2. Zacks research analysts are highly pessimistic on the counter and has given it a short term rating of 5, indicating that it is a Underperform ...
Sanofi SA (ADR) (SNY) Launches Inhaled Insulin Afrezza
Sanofi SA (ADR) (NYSE:SNY) has launched its inhalable insulin Afrezza in the US, the company announced before the US markets opened for trading Tuesday.
Sanofi SA (SNY) Q4 Earnings Preview
Sanofi SA (ADR) (NYSE:SNY) is scheduled to announce its financial results for the fourth quarter of fiscal year 2014 (4QFY14) on Thursday, February 5 before the market opens.
Zacks Rating Disclosure on Sanofi SA (ADR)  Wall Street Pulse
Shares of Sanofi SA (ADR) Sinks by -1.69% for the Week  Winston View
Sanofi SA (ADR) Analyst Rating Update
Research firm Zacks has rated Sanofi SA (ADR) (NYSE:SNY) and has ranked it at 5, indicating that its shares are a Underperform.
Sanofi SA (ADR) Price Target Update  Bar and Graph Report
Share Price of Sanofi SA (ADR) Rally 2.85%  Winston View
Company Shares of Sanofi SA (ADR) Rally 1.38%
The short ratio of Sanofi SA (ADR) (NYSE:SNY) is 1.42. On a monthly basis, the short interest has registered a change of 93.1%.
First Call Recommends Buy on Sanofi SA (ADR)
Sanofi SA (ADR) (NYSE:SNY): First Call has rated the counter a Buy. The rating recommendation was disclosed in the First Call research information.
Company Shares of Sanofi SA (ADR) Rally 4.25%  Ashburn Daily
Sanofi SA (ADR) Witness Inflow of Net $1.65M  Markets Bureau